e-NOBORI Observational Registry of Nobori DES
Sponsor
Terumo Europe N.V. (Industry)
Overall Status
Completed
CT.gov ID
NCT01261273
Collaborator
(none)
18,000
257
69.1
70
1
Study Details
Study Description
Brief Summary
Title Prospective, single-arm, multi-centre, observational registry to further validate safety and efficacy of the Nobori® DES in real-world patients.
Objective Primary objective The primary objective of e-NOBORI registry is to further validate the safety and efficacy of Nobori® DES system in unselected patients representing everyday clinical practice.
Primary Endpoint: Freedom from Target Lesion Failure (TLF) defined as a composite of cardiac death, target vessel related myocardial infarction (MI) and clinically driven target lesion revascularization (TLR) at 1 year
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
-
Title Prospective, single-arm, multi-centre, observational registry to further validate safety and efficacy of the Nobori® DES in real-world patients.
-
Primary objective The primary objective of e-NOBORI registry is to further validate the safety and efficacy of Nobori® DES system in unselected patients representing everyday clinical practice.
-
Primary Endpoint: Freedom from Target Lesion Failure (TLF) defined as a composite of cardiac death, target vessel related myocardial infarction (MI) and clinically driven target lesion revascularization (TLR) at 1 year
-
Clinical Site Locations:
Up to 200 centres across Europe, Asia and Central and South America
-Patient Population : ~18000 eligible patients suitable for treatment with the Nobori® DES will be entered in the e-NOBORI registry
Eligibility Criteria
-
Patient is more or equal 18 years old;
-
Patient is, according to hospital routine practice, eligible for percutaneous coronary intervention using DES (and RVD matches available Nobori® DES sizes);
-
Patient has been informed of the nature of the study and agrees to its provisions, has provided written informed consent as approved by the Institutional Review Board/Ethics Committee of the respective clinical site, wherever such requirement exists.
NOTE: In order to avoid bias it is recommended that all investigators aim to enrol all consecutive patients complying with study eligibility criteria. It is also desirable to have at least two cardiologists as investigators in each centre.
According to pre-specified criteria, patients will be automatically allocated to one or more sub-studies as following:
-
NOBORI Acute Coronary Syndrome
-
NOBORI Stable angina
-
NOBORI Female
-
NOBORI Bifurcation
-
NOBORI Diabetes
-
Insulin Dependent Diabetes Mellitus (IDDM)
-
Non-Insulin Dependent Diabetes Mellitus (NIDDM)
-
NOBORI Small Vessels (less or equal 2.75mm)
-
NOBORI Long Lesions (more or equal 20mm)
-
NOBORI Renal Insufficiency (> 2.0 mg/dL - 176 µmol/mL)
-
NOBORI Elderly (more or equal 80 years of age)
-
NOBORI Restenosis
-
NOBORI Multivessel Treatment
-
NOBORI Complex Lesions
In addition to above mentioned sub-studies there will be geographic sub-studies for the main areas.
Medication Pre-Procedure: According to hospital routine practice Post-Procedure: Mandatory antiplatelet treatment, according to hospital routine practice (minimum 6 months DAT)
Study Design
Study Type:
Observational
Actual Enrollment
:
18000 participants
Observational Model:
Other
Time Perspective:
Prospective
Official Title:
Prospective, Single-Arm, Multi-Centre, Observational Registry to Further Validate Safety and Efficacy of the Nobori DES in Real-World Patients
Actual Study Start Date
:
Aug 25, 2010
Actual Primary Completion Date
:
May 1, 2016
Actual Study Completion Date
:
May 27, 2016
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Stable angina Patient admitted with stable angina |
|
| Acute Coronary Syndrome Patients admitted with Acute Coronary Syndrome |
|
| Female Participant female patients |
|
| Bifurcation One or more lesions treated during the baseline in bifurcation |
|
| Insulin Dependent Diabetes Mellitus Patients that were insulin-dependent diabetes mellitus at admission |
|
| Non-Insulin Dependent Diabetes Mellitus Patients that were non-insulin-dependent diabetes mellitus at admission |
|
| Small Vessels vessels smaller or equal to 2.75mm |
|
| NOBORI Long Lesions Lesions longer or equal to 20mm |
|
| Renal Insufficiency Patients that at admission had renal insufficiency (> 2.0 mg/dL - 176 µmol/mL) at admission |
|
| Elderly Patients more or equal 80 years old |
|
| Restenosis One or more lesions treated during the baseline in were restenotic lesions |
|
| Multivessel Treatment Patients who underwent the treatment of more than 1 vessel during the index procedure |
|
| Complex Lesions Patients who underwent a PCI on the Left Main Trunk, on a Chronic Total Occluded lesion or located on a Saphenous Vein Graft |
|
| Overall Total Population |
Outcome Measures
Primary Outcome Measures
- FREEDOM OF TARGET LESION FAILURE [1 YEAR]
TLF: COMPOSITE OF CARDIAC DEATH, MYOCARDIAL INFARCTION AND TARGET LESION REVASCULARIZATION
Secondary Outcome Measures
- Procedural success [1 MONTH]
Procedural success is defined as achievement of a diameter of stenosis of <30% by visual assessment and/or <50% by QCA, using any percutaneous method, without the occurrence of death, MI, or repeat revascularization of the target lesión during the hospital stay.
- Device success [1 MONTH]
Device Success defined as attainment of a final residual diameter stenosis of the target lesion of < 30% by visual assessment and/or < 50% by QCA, using the assigned device only. Device Success defined as attainment of a final residual diameter stenosis of the target lesion of < 30% by visual assessment and/or < 50% by QCA, using the assigned device only. Device success is defined as attainment of a final residual diameter stenosis of the target lesión of <30% by visual assessment and/or >50% QCA, using the assigned device only.
- Acute/subacute stent thrombosis [1 MONTH]
(definite/probable according to ARC definitions)
- Peri-procedural myocardial infarction [1 MONTH]
Peri-procedural myocardial infarction
- Rate of Major Adverse Cardiac Events (MACE) [1 MONTH]
Major Adverse Cardiac Events (MACE) defined as a composite of cardiac death, MI or clinically driven target vessel revascularization (TVR)
- Major vascular and bleeding complications [1 MONTH]
NOT CABG RELATED
- Cardiac death/ Myocardial Infarction [1 AND 2 YEARS]
Cardiac death/ Myocardial Infarction
- Clinically driven target lesion revascularization (TLR) [1 & 2 YEARS]
re-PCI or CABG involving target lesion
- Stent thrombosis [1 AND 2 YEARS]
(definite/probable; ARC definition)
- Clinically driven target vessel revascularization (TVR) [1 AND 2 YEARS]
PCI AND CABG
- Target Lesion Failure (TLF) [1 MONTH AND 2 YEARS]
Defined as a composite of cardiac death, target vessel related myocardial infarction (MI) and clinically driven target lesion revascularization
- Patient Oriented Composite Endpoint defined as any cause of mortality, MI (Q-wave and non Q-wave), or any TVR [1 MONTH, 1 AND 2 YEARS]
Patient Oriented Composite Endpoint defined as any cause of mortality, MI (Q-wave and non Q-wave), or any TVR
- Composite Endpoint of Cardiac death and MI [1 MONTH, 1 AND 2 YEARS]
Composite Endpoint of Cardiac death and MI
- Composite Endpoint of Cardiac death and post-procedural MI [1 month, 1 and 2 years post-procedure]
Composite Endpoint of Cardiac death and post-procedural MI
- Stent thrombosis [1 month, 1 and 2 years post-procedure]
definite and probable according to ARC definitions
- Primary Stent thrombosis [1 month, 1 and 2 years post-procedure]
definite and probable according to ARC definitions
- Secondary Stent thrombosis [1 month, 1 and 2 years post-procedure]
definite and probable according to ARC definitions
- Duration of dual antiplatelet therapy [UP TO 2 YEARS]
Duration of dual antiplatelet therapy
- Composite Endpoint of Cardiac death, post-procedural MI and stent thrombosis rate during the course of DAT versus the same events after cessation of DAT [UP TO 2 YEARS]
Composite Endpoint of Cardiac death, post-procedural MI and stent thrombosis rate during the course of DAT versus the same events after cessation of DAT
- Clinically driven Target Lesion Revascularization [1 MONTH]
Clinically driven Target Lesion Revascularization
- Clinically driven Target Vessel Revascularization [1 MONTH]
Clinically driven Target Vessel Revascularization
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
Patient is more or equal 18 years old;
-
Patient is, according to hospital routine practice, eligible for percutaneous coronary intervention using DES (and RVD matches available Nobori® DES sizes);
-
Patient has been informed of the nature of the study and agrees to its provisions, has provided written informed consent as approved by the Institutional Review Board/Ethics Committee of the respective clinical site, wherever such requirement exists.
Exclusion Criteria:
- None
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | SMZ-Donauspital Vienna | Vienna | Austria | ||
| 2 | National Heart Foundation Hospital & Research Institute | Dhaka | Bangladesh | ||
| 3 | Republican Clinical Medical Center (Presidential Hospital) | Minsk | Belarus | ||
| 4 | Republican Scientific and Practical Center of Cardiology | Minsk | Belarus | ||
| 5 | Mogilev Regional Clinical Hospital | Mogilev | Belarus | ||
| 6 | Hospital Madre Teresa | Belo Horizonte | Brazil | ||
| 7 | Hospital Santa Isabel-Sociedade Divina Providência | Blumenau | Brazil | ||
| 8 | HMCP PUC-Campinas | Campinas | Brazil | ||
| 9 | Hospital E Maternidade Madre Teodora | Campinas | Brazil | ||
| 10 | Hospital Vera Cruz Campinas | Campinas | Brazil | ||
| 11 | Hospital Geral Universitário | Cuiaba | Brazil | ||
| 12 | Hospital Cruz Vermelha Brasileira Filial do Paraná | Curitiba | Brazil | ||
| 13 | Hospital Nossa Senhora das Graças | Curitiba | Brazil | ||
| 14 | Hospital Santa Cruz | Curitiba | Brazil | ||
| 15 | Hospital Monte Sinai (Juiz de Fora) | Juiz de Fora | Brazil | ||
| 16 | Instituto Cardiovascular de Linhares (Unicor) | Linhares | Brazil | ||
| 17 | Hospital do Coração de Londrina | Londrina | Brazil | ||
| 18 | Irmandade da Santa Casa de Misericórdia de Marília | Marilia | Brazil | ||
| 19 | Hospital Paraná | Maringá | Brazil | ||
| 20 | Hospital Procordis | Niterói | Brazil | ||
| 21 | Hospital Vera Cruz Patos de Minas | Patos de Minas | Brazil | ||
| 22 | Hospital Moinhos de Vento | Porto Alegre | Brazil | ||
| 23 | Hospital Mãe De Deus | Porto Alegre | Brazil | ||
| 24 | Hospital São Lucas - PUCRS | Porto Alegre | Brazil | ||
| 25 | Clinica Status Cor | Rio de Janeiro | Brazil | ||
| 26 | Hospital Naval Marcíllo Dias | rio de Janeiro | Brazil | ||
| 27 | Fundação Bahiana de Cardiologia (MC Oliveira Prest | Salvador | Brazil | ||
| 28 | Hospital Beneficencia Portuguesa de Sao Paulo | Sao Joao do Paraiso | Brazil | ||
| 29 | Casa de Saude Santa Marcelina | Sao Paulo | Brazil | ||
| 30 | Hospital Albert Einstein | Sao Paulo | Brazil | ||
| 31 | Hospital Bandeirantes | Sao Paulo | Brazil | ||
| 32 | Hospital Ana Costa (ENDOCOR Serviços Médicos Ltda) | Sao Vicente | Brazil | ||
| 33 | Instituto Dante Pazzanese | São Paulo | Brazil | ||
| 34 | Real e Benemérita Assoção Portuguesa de Beneficênc | São Paulo | Brazil | ||
| 35 | Hospital Anchieta Ltda. | Taguatinga | Brazil | ||
| 36 | Instituto do Coração do Triângulo Mineiro | Uberlândia | Brazil | ||
| 37 | Insituto de Cardiologia Espirito Santo | Vitória | Brazil | ||
| 38 | Tokuda Hospital Sofia | Sofia | Bulgaria | ||
| 39 | Hospital Militar de Santiago | La Reina | Chile | ||
| 40 | clinica Santa Maria | Santiago de Chile | Chile | ||
| 41 | Instituto Nacional del Torax | Santiago | Chile | ||
| 42 | San Juan de Dios | Santiago | Chile | ||
| 43 | Las Higueras De Talcahuano | Talcahuano | Chile | ||
| 44 | V Region (Hospital Gustavo Fricke, Hospital Van Buren, Clinica Reñaca) | Valparaíso | Chile | ||
| 45 | Clinica alemana de Santiago | Vitacura | Chile | ||
| 46 | St. Anne University Hospital | Brno | Czechia | ||
| 47 | Nemocnice Na Homolce | Praha | Czechia | 15030 | |
| 48 | Gentofte Hospital (M12FU) | Hellerup | Denmark | ||
| 49 | ALHYATT Cardiovascular Center | Alexandria | Egypt | ||
| 50 | International Cardiac Center | Alexandria | Egypt | ||
| 51 | AL Amal | Cairo | Egypt | ||
| 52 | Al Nakhil hospital | Cairo | Egypt | ||
| 53 | AS-Salam Mohndseen | Cairo | Egypt | ||
| 54 | Cleopatra | Cairo | Egypt | ||
| 55 | Egyheart - cath lab | Cairo | Egypt | ||
| 56 | El Dorah Heart Care Center | Cairo | Egypt | ||
| 57 | Hayat Hospital | Cairo | Egypt | ||
| 58 | (DAFH) Dar Al Fouad Hospital | Giza | Egypt | ||
| 59 | Alfa | Giza | Egypt | ||
| 60 | ICS center | Giza | Egypt | ||
| 61 | RCC Cardiac center | Giza | Egypt | ||
| 62 | Glory cardiac center - Cath group | Mansourah | Egypt | ||
| 63 | Al Noor Cath Lab | Sohag | Egypt | ||
| 64 | Om El kora cardiac center | Tanta | Egypt | ||
| 65 | East Tallinn Central Hospital | Tallin | Estonia | ||
| 66 | North-Estonia Regional Hospital | Tallin | Estonia | ||
| 67 | Clinique de l'Europe à Amiens (SAS Cardio Amiens) | Amiens | France | ||
| 68 | CHU Angers | Angers | France | ||
| 69 | Hôpital Privé d'Antony | Antony | France | ||
| 70 | Hopital La Roseraie | Aubervilliers | France | ||
| 71 | CH Avignon | Avignon | France | ||
| 72 | Clinique Rhone Durance | Avignon | France | ||
| 73 | CH Bastia | Bastia Cedex | France | ||
| 74 | Clinique La Fourcade | Bayonne | France | ||
| 75 | Clinique Bois Bernard à Bois Bernard | Bois-Bernard | France | ||
| 76 | Clinique Saint Augustin | Bordeaux | France | ||
| 77 | CHU de la Cavale Blanche | Brest | France | ||
| 78 | CH Privé Saint - Martin Caen | Caen | France | ||
| 79 | CHU de la Cote de Nacre (CHU Caen) | Caen | France | ||
| 80 | Hopital Albert Schweitzer-Colmar | Colmar | France | ||
| 81 | CH Sud Francilien | Corbeil Essonnes | France | ||
| 82 | Clinique des Cèdres-Dr Brunelle | Cornebarrieu | France | ||
| 83 | Clinique des Cèdres-Dr.Tauzin | Cornebarrieu | France | ||
| 84 | Centre Cardiologique d'Evecquemont | Evecquemont | France | ||
| 85 | CH Haguenau | Haguenau | France | ||
| 86 | CH de Lagny-Marne La Vallée | Jossigny | France | ||
| 87 | CH de Cornouaille | La Cornuaille | France | ||
| 88 | CH La Roche sur Yon | La Roche sur Yon | France | ||
| 89 | CH de Chartres | Le Coudray | France | ||
| 90 | CC Marie Lannelongue | Le Plessis Robinson | France | ||
| 91 | Clinique La Louviere | Lille | France | ||
| 92 | CH Dupuytren Limoges | Limoges Cedex | France | ||
| 93 | CH Lorient | Lorient | France | ||
| 94 | Institut Hospitalier Jacques Cartier (ICPS Massy) | Massy | France | ||
| 95 | Clinique les Fontaines | Melun | France | ||
| 96 | Clinique du Millenaire | Montpellier | France | ||
| 97 | Association Clinique Bizet | Paris | France | ||
| 98 | Clinique Turin - Paris | Paris | France | ||
| 99 | Hopital Lariboisière | Paris | France | ||
| 100 | Hopital Pitié Salpétrière | Paris | France | ||
| 101 | Hôpital du Val de Grâce | Paris | France | ||
| 102 | Hôpital Europeen Georges Pompidou (HEGP) | Paris | France | ||
| 103 | CH Pau | Pau | France | ||
| 104 | CH Périgueux | Perigueux | France | ||
| 105 | CH Général Maréchal Joffre Perpignan | Perpignan | France | ||
| 106 | Clinique Saint-Martin Pessac | Pessac | France | ||
| 107 | CHU La Miletrie Poitiers | Poitiers | France | ||
| 108 | CH René Dubos | Pontoise | France | ||
| 109 | Hopital Claude Galien | Quincy | France | ||
| 110 | Clinique Saint Laurent | Rennes | France | ||
| 111 | Hôpital Jacques Puel (CH de Rodez) | Rodez | France | ||
| 112 | Clinique Saint Hilaire | Rouen | France | ||
| 113 | Centre Cardiologique du Nord | Saint Denis | France | ||
| 114 | NHC Strasbourg | Strasbourg | France | ||
| 115 | Clinique de l'Ormeau - CCV des Pyrenées | Tarbes | France | ||
| 116 | Polyclinique du Parc Toulouse | Toulouse | France | ||
| 117 | CH Valence | Valence | France | ||
| 118 | Clinique Vauban | Valenciennes | France | ||
| 119 | CH Bretagne Atlantique | Vannes | France | ||
| 120 | JoAnn Medical Center | Tbilisi | Georgia | ||
| 121 | Zentralklinik Bad Berka GmbH | Bad Berka | Germany | ||
| 122 | Herz-und Diabeteszentrum Nordrhein-Westfalen | Bad Oeynhausen | Germany | ||
| 123 | Evangelisch Freikirchliches Krankenhaus und Herzze | Berlin | Germany | ||
| 124 | Gemeinschaftskrankenhaus Havelhöhe | Berlin | Germany | ||
| 125 | Jüdisches Krankenhaus | Berlin | Germany | ||
| 126 | Klinikum Neukölln | Berlin | Germany | ||
| 127 | Vivantes Klinkum Spandau | Berlin | Germany | ||
| 128 | Vivantes Netzwerk für Gesundheit gmbH - Am Urban | Berlin | Germany | ||
| 129 | Vivantes Netzwerk für Gesundheit gmbH - Friedrichs | Berlin | Germany | ||
| 130 | Vivantes Netzwerk für Gesundheit gmbH - Humboldt | Berlin | Germany | ||
| 131 | Ev.Bethesda-Johanniter Klinikum Duisburg GmbH | Duisburg | Germany | ||
| 132 | Klinikum Fulda | Fulda | Germany | ||
| 133 | Uniklinik Schleswig-Holstein, Campus Kiel | Kiel | Germany | ||
| 134 | Herzzentrum Leipzig-Rhöne Klinikum | Leipzig | Germany | ||
| 135 | St. Marienhospital Lünen | Lünen | Germany | ||
| 136 | Klinikum Oldenburg | Oldenburg | Germany | ||
| 137 | Universitätsklinik Rostock | Rostock | Germany | ||
| 138 | Evang.Diakonieanstalt Speyer | Speyer | Germany | ||
| 139 | Gottsegen National Cardiology Institute (GOKI) | Budapest | Hungary | ||
| 140 | Semmelweis University Cardiology Centre | Budapest | Hungary | ||
| 141 | Fejér Megyei Szent György Kórház | Székesfehérvár | Hungary | ||
| 142 | Medistra Hospital | Jakarta | Indonesia | ||
| 143 | National Cardiovascular Center Harapan Kita | Jakarta | Indonesia | ||
| 144 | Dr. Soetomo General Hospital, Surabaya | Surabaya | Indonesia | ||
| 145 | Beaumont Hospital | Dublin | Ireland | ||
| 146 | University Hospital Galway | Galway | Ireland | ||
| 147 | Rambam Medical centre | Haifa | Israel | ||
| 148 | Wolfson Medical Center | Holon | Israel | 58100 | |
| 149 | Meir Medical Center, Kfar-Saba | Kfar-Saba | Israel | ||
| 150 | Laniado Medical Center | Netanya | Israel | ||
| 151 | Rabin Medical Center | Petah Tikva | Israel | ||
| 152 | Kaplan Hospital | Rehovot | Israel | ||
| 153 | Invasive Cardiology Laboratory of Clinics "Gailezers" of Riga's Eastern Clinical University Hospital | Riga | Latvia | ||
| 154 | Invasive Cardiology Laboratory of P. Stradins Clinical University Hospital | Riga | Latvia | ||
| 155 | Hospital of Lithuania University of Health Science | Kaunas | Lithuania | ||
| 156 | Mater Dei | Msida | Malta | ||
| 157 | 1e de Octubre ISSSTE | Ciudad de Mexico | Mexico | ||
| 158 | Hospital Angeles Culiacan | Culiacán | Mexico | ||
| 159 | Hospital Angeles Leon | León, Guanajuato | Mexico | ||
| 160 | Hospital Star Medica Mérida Yucatán | Merida, Yucatan | Mexico | ||
| 161 | Hospital Central Militar | Mexico City | Mexico | ||
| 162 | Hospital Angeles Mocel | Mexico DF | Mexico | ||
| 163 | Hospital de Cardiologia C.M.N. | Mexico DF | Mexico | ||
| 164 | Instituto Nacional De Cardiologia "Ignacio Chávez" | Mexico DF | Mexico | ||
| 165 | Centro Médico Nacional 20 de Noviembre | Mexico, D.F. | Mexico | ||
| 166 | Hospital Universitario Dr. José Eleuterio Gonzalez | Monterrey, Nuevo León | Mexico | ||
| 167 | Dalinde Medical Center | México, DF | Mexico | ||
| 168 | Hospital Lomas de San Luis Internacional | San Luis Potosi SLP | Mexico | ||
| 169 | Amphia Hospital | Breda | Netherlands | ||
| 170 | Medisch Centrum Haaglanden | Den Haag | Netherlands | ||
| 171 | Albert Schweitzer Hospital | Dordrecht | Netherlands | ||
| 172 | Jeroen Bosch Ziekenhuis | s'Hertogenbosch | Netherlands | ||
| 173 | St Adalbert Speciality Hospital | Gdansk | Poland | ||
| 174 | Szpital Klinicznk Przemienienia (University Hospital) | Poznan | Poland | ||
| 175 | Szpital Wojewodzski Poznaniu | Poznan | Poland | ||
| 176 | Cardiolife Hospital Timisoara | Timisoara | Romania | 300014 | |
| 177 | Chelyabinsk Regional Clinical Hospital | Chelyabinsk | Russian Federation | ||
| 178 | Military Hospital N3 named by Vishnevsky | Krasnogorsk | Russian Federation | ||
| 179 | State cardiovascular center based on regional clin | Krasnoyarsk | Russian Federation | ||
| 180 | Regional Clinical Hospital | Kursk | Russian Federation | ||
| 181 | Central Clinical Hospital N°2 Russia Railways | Moscow | Russian Federation | ||
| 182 | Academian E.N Meshalkin State Research Institute of circulation Pathology | Novosibirsk | Russian Federation | 630055 | |
| 183 | Federal cardiosurgerical center, Penza | Penza | Russian Federation | ||
| 184 | Federal center of heart,blood and endocrinology diseases named by Almazov | Saint-Petersburg | Russian Federation | ||
| 185 | Saratov Research Institute of science for cardiology | Saratov | Russian Federation | ||
| 186 | Kirochnaya str.41 | St-Petersburg | Russian Federation | 191015 | |
| 187 | Regional Vessel Center | Ufa | Russian Federation | ||
| 188 | Ufa city Emergency Hospital | Ufa | Russian Federation | ||
| 189 | Institute for Cardiovascular Disease Dedinje | Dedinje | Serbia | ||
| 190 | Clinical Center Kragujevac | Kragujevac | Serbia | ||
| 191 | Clinical Center of Niš | Niš | Serbia | ||
| 192 | CH Celje | Celje | Slovenia | ||
| 193 | Hospital general de Albacete | Albacete | Spain | ||
| 194 | Hospital San Juan | Alicante | Spain | ||
| 195 | Hospital Torrecárdenas | Almeria | Spain | ||
| 196 | Hospital G. Trias i Pujol | Badalona | Spain | ||
| 197 | Hospital Bellvitge | Barcelona | Spain | ||
| 198 | Hospital Sant Pau | Barcelona | Spain | ||
| 199 | Hospital de Cruces-Barakaldo | Bilbao- Vizcaya | Spain | ||
| 200 | Hospital de Galdakao | Bizkaia | Spain | ||
| 201 | Hospital San Pedro de Alcantara-Caceres | Caceres | Spain | ||
| 202 | Hospital Nostra Señora Rossell | Cartagena | Spain | ||
| 203 | Hospital General de Castellón | Castellón | Spain | ||
| 204 | Hospital Nostra Señora Alarcos | Ciudad Real | Spain | ||
| 205 | Hospital Cabueñes | Gijón | Spain | ||
| 206 | Hospital Universitario de Guadalajara | Guadalajara | Spain | ||
| 207 | Hospital Juan Canalejo | La Coruña | Spain | ||
| 208 | Hospital San Rafael | La Coruña | Spain | ||
| 209 | Clinica San Roque | Las Palmas | Spain | ||
| 210 | Hospital de León | León | Spain | ||
| 211 | Clínica Moncloa | Madrid | Spain | ||
| 212 | Hospital Fundacion Alcorcon | Madrid | Spain | ||
| 213 | Hospital Puerta de Hierro | Majadahonda-Madrid | Spain | ||
| 214 | Hospital Virgen Arrixaca | Murcia | Spain | ||
| 215 | Universitario central de Asturias | Oviedo | Spain | ||
| 216 | Hospital Clínico Universitario de Salamanca | Salamanca | Spain | ||
| 217 | Hospital Clínico Universitario de Santiago de Compostela | Santiago de Compostela | Spain | ||
| 218 | Hospital Candelaria | Tenerife | Spain | ||
| 219 | Hospital Virgen Salud | Toledo | Spain | ||
| 220 | Clínico Universitario Valencia | Valencia | Spain | ||
| 221 | Hospital Manises | Valencia | Spain | ||
| 222 | Hospital Meixoeiro-MEDTEC | Vigo | Spain | ||
| 223 | Hospital Txagorritxu | Vitoria | Spain | ||
| 224 | Hospital Miguel Servet | Zaragoza | Spain | ||
| 225 | Falun Lasarett | Falun | Sweden | ||
| 226 | University Hospital Linköping | Linköping | Sweden | ||
| 227 | Uppsala Akademiska Sjukhus, Kardiologkliniken | Uppsala | Sweden | ||
| 228 | Central Lasarettet i Västerås, Angio/PCI lab. Medi | Västerås | Sweden | ||
| 229 | E-da Hospital/Kaohsiung | Kaohsiung | Taiwan | ||
| 230 | Taichung Veterans General Hospital | Taichung R.O.C. | Taiwan | ||
| 231 | Chi Mei Medical Center/Tainan | Tainan | Taiwan | ||
| 232 | National Cheng Kung University Hospital | Tainan | Taiwan | ||
| 233 | Cheng Hsin General Hospital / Taipei | Taipei | Taiwan | ||
| 234 | National Taiwan University Hospital | Taipei | Taiwan | ||
| 235 | Taipei Veterans General Hospital, VACRS | Taipei | Taiwan | ||
| 236 | Kharkov Regional Hospital | Kharkov | Ukraine | ||
| 237 | Feofaniya | Kiev | Ukraine | ||
| 238 | Ukrainian Institute of Cardiology | Kiev | Ukraine | ||
| 239 | National Institute of Cardiovascular Surgery AMS | Kyiv | Ukraine | ||
| 240 | Queen Elizabeth Birmingham | Birmingham | United Kingdom | ||
| 241 | Royal Blackpool hospital (Lancashire Heart Centre) | Blackpool | United Kingdom | ||
| 242 | Royal Cornwall hospital | Cornwell | United Kingdom | ||
| 243 | Castle Hill Hospital | Cottingham | United Kingdom | ||
| 244 | Southern Health and Social Care Trust Craigavon Ar | Craigavon | United Kingdom | ||
| 245 | Scunthorpe general hospital | District Of North East Lincolnshire | United Kingdom | ||
| 246 | Dorset county Hospital | Dorset | United Kingdom | ||
| 247 | Eastbourne General | Eastbourne | United Kingdom | ||
| 248 | Glenfield general hospital | Glenfield | United Kingdom | ||
| 249 | Conquest Hospital Hastings | Hastings | United Kingdom | ||
| 250 | Kettering General Hospital | Kettering | United Kingdom | ||
| 251 | Northwick Park | London | United Kingdom | ||
| 252 | Freeman Hospital | Newcastle upon Tyne | United Kingdom | ||
| 253 | Royal Gwent Hospital | Newport | United Kingdom | ||
| 254 | Fairfield General Hospital | North Manchester | United Kingdom | ||
| 255 | Frimley Park Hospital NHS Foundation Trust | Surrey | United Kingdom | ||
| 256 | Pinderfield General Hospital | Wakefield | United Kingdom | ||
| 257 | New Cross Wolverhampton | Wednesfield | United Kingdom |
Sponsors and Collaborators
- Terumo Europe N.V.
Investigators
- Study Chair: Dragica Paunovic, Dr., Terumo Europe
Study Documents (Full-Text)
None provided.More Information
Publications
- Berger JS, Elliott L, Gallup D, Roe M, Granger CB, Armstrong PW, Simes RJ, White HD, Van de Werf F, Topol EJ, Hochman JS, Newby LK, Harrington RA, Califf RM, Becker RC, Douglas PS. Sex differences in mortality following acute coronary syndromes. JAMA. 2009 Aug 26;302(8):874-82. doi: 10.1001/jama.2009.1227.
- Boccara F, Teiger E, Cohen A. Role of drug eluting stents in diabetic patients. Heart. 2006 May;92(5):579-81. Epub 2006 Jan 31.
- Braunwald E. Unstable angina. A classification. Circulation. 1989 Aug;80(2):410-4.
- Briguori C, Airoldi F, Chieffo A, Carlino M, Montorfano M, Colombo A. Renal function and drug-eluting stent. Int J Cardiol. 2010 Jun 25;142(1):92-4. doi: 10.1016/j.ijcard.2008.11.138. Epub 2009 Jan 15.
- Chevalier B, Serruys PW, Silber S, Garcia E, Suryapranata H, Hauptmann K, Wijns W, Schuler G, Fath-Ordoubadi F, Worthley S, Thuesen L, Meredith I, Bressers M, Nagai H, Paunovic D. Randomised comparison of Nobori, biolimus A9-eluting coronary stent with a Taxus(R), paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the Nobori 1 trial. EuroIntervention. 2007 Feb;2(4):426-34.
- Chevalier B, Silber S, Park SJ, Garcia E, Schuler G, Suryapranata H, Koolen J, Hauptmann KE, Wijns W, Morice MC, Carrie D, van Es GA, Nagai H, Detiege D, Paunovic D, Serruys PW; NOBORI 1 Clinical Investigators. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial--Phase 2. Circ Cardiovasc Interv. 2009 Jun;2(3):188-95. doi: 10.1161/CIRCINTERVENTIONS.108.823443. Epub 2009 May 8.
- Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007 May 1;115(17):2344-51.
- Detre KM, Holmes DR Jr, Holubkov R, Cowley MJ, Bourassa MG, Faxon DP, Dorros GR, Bentivoglio LG, Kent KM, Myler RK. Incidence and consequences of periprocedural occlusion. The 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation. 1990 Sep;82(3):739-50.
- Elezi S, Kastrati A, Pache J, Wehinger A, Hadamitzky M, Dirschinger J, Neumann FJ, Schömig A. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol. 1998 Dec;32(7):1866-73.
- Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med. 1994 Aug 25;331(8):496-501.
- Galløe AM, Thuesen L, Kelbaek H, Thayssen P, Rasmussen K, Hansen PR, Bligaard N, Saunamäki K, Junker A, Aarøe J, Abildgaard U, Ravkilde J, Engstrøm T, Jensen JS, Andersen HR, Bøtker HE, Galatius S, Kristensen SD, Madsen JK, Krusell LR, Abildstrøm SZ, Stephansen GB, Lassen JF; SORT OUT II Investigators. Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial. JAMA. 2008 Jan 30;299(4):409-16. doi: 10.1001/jama.299.4.409.
- Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, Russell ME. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003 Jan 7;107(1):38-42.
- Grube E, Spirit V registry: one-year follow-up. EuroIntervention 2009; 5
- Hamm CW, Braunwald E. A classification of unstable angina revisited. Circulation. 2000 Jul 4;102(1):118-22. Review.
- Hannan EL, Wu C, Walford G, Culliford AT, Gold JP, Smith CR, Higgins RS, Carlson RE, Jones RH. Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. N Engl J Med. 2008 Jan 24;358(4):331-41. doi: 10.1056/NEJMoa071804.
- Holmes DR Jr, Holubkov R, Vlietstra RE, Kelsey SF, Reeder GS, Dorros G, Williams DO, Cowley MJ, Faxon DP, Kent KM, et al. Comparison of complications during percutaneous transluminal coronary angioplasty from 1977 to 1981 and from 1985 to 1986: the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. J Am Coll Cardiol. 1988 Nov;12(5):1149-55.
- Holmes DR Jr, Leon MB, Moses JW, Popma JJ, Cutlip D, Fitzgerald PJ, Brown C, Fischell T, Wong SC, Midei M, Snead D, Kuntz RE. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation. 2004 Feb 10;109(5):634-40.
- Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005 May 4;293(17):2126-30.
- Jain AK, Meredith IT, Lotan C, Rothman MT, Pateraki S; E-Five Investigators. Real-world safety and efficacy of the endeavor zotarolimus-eluting stent: early data from the E-Five Registry. Am J Cardiol. 2007 Oct 22;100(8B):77M-83M.
- Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, Smits PC. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet. 2010 Jan 16;375(9710):201-9. doi: 10.1016/S0140-6736(09)62127-9. Epub 2010 Jan 7.
- Kim YH, Park SW, Lee SW, Park DW, Yun SC, Lee CW, Hong MK, Kim HS, Ko JK, Park JH, Lee JH, Choi SW, Seong IW, Cho YH, Lee NH, Kim JH, Chun KJ, Park SJ; Long-DES-II Study Investigators. Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease. Circulation. 2006 Nov 14;114(20):2148-53. Epub 2006 Oct 23.
- Latif F, Kleiman NS, Cohen DJ, Pencina MJ, Yen CH, Cutlip DE, Moliterno DJ, Nassif D, Lopez JJ, Saucedo JF; EVENT Investigators. In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: a report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. JACC Cardiovasc Interv. 2009 Jan;2(1):37-45. doi: 10.1016/j.jcin.2008.06.012.
- Lotan C, Almagor Y, Kuiper K, Suttorp MJ, Wijns W. Sirolimus-eluting stent in chronic total occlusion: the SICTO study. J Interv Cardiol. 2006 Aug;19(4):307-12.
- Mehilli J, Dibra A, Kastrati A, Pache J, Dirschinger J, Schömig A; Intracoronary Drug-Eluting Stenting to Abrogate Restenosis in Small Arteries (ISAR-SMART 3) Study Investigators. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Eur Heart J. 2006 Feb;27(3):260-6. Epub 2006 Jan 9.
- Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnàr F, Falotico R; RAVEL Study Group. Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with de Novo Native Coronary Artery Lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002 Jun 6;346(23):1773-80.
- Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE; SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003 Oct 2;349(14):1315-23.
- Nakamura S, Nakamura S, Ogawa H, Bae JH, HansCahyadi Y, Udayachalerm W, DTresukosol D, Tansuphaswadikul S, Drug-eluting stents for the treatment of chronic total occlusion: a comparison with sirolimus, paclitaxel, zotarolimus, BiolimusA9, EPC capture and everolimus-eluting stent: multicenter registry in Asia (Poster Contributions Georgia World Congress Center, Hall B5 Monday, March 15, 2010, 9:30 a.m.-10:30 a.m. ). J Am Coll Cardiol 2010;55.
- Nakamura S, Nakamura S, Ogawa H, Bae JH, HansCahyadi Y, Udayachalerm W, DTresukosol D, Tansuphaswadikul S, Drug-eluting stents for the treatment of left main coronary artery disease with sirolimus, paclitaxel, zotarolimus, BiolimusA9, EPC capture and everolimus-eluting stent: multicenter registry in Asia (Oral Contributions Georgia World Congress Center, Room B315 Monday, March 15, 2010, 2:00 p.m.-2:12 p.m.). J Am Coll Cardiol 2010;55
- Novack V, Cutlip D, Kleiman N, Pencina M, Mauri L, Yen CH, Berger P, Goldberg S, Kellett M, Waksman R, Hong M, Raizner AE, Cohen DJ. In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. JACC Cardiovasc Interv. 2009 Aug;2(8):767-75. doi: 10.1016/j.jcin.2009.05.016.
- Ong AT, van Domburg RT, Aoki J, Sonnenschein K, Lemos PA, Serruys PW. Sirolimus-eluting stents remain superior to bare-metal stents at two years: medium-term results from the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. J Am Coll Cardiol. 2006 Apr 4;47(7):1356-60. Epub 2006 Mar 20.
- Ortolani P, Marzocchi A, Marrozzini C, Palmerini T, Saia F, Taglieri N, Aquilina M, Baldazzi F, Silenzi S, Cooke RM, Reggiani ML, Branzi A. Randomized comparative trial of a thin-strut bare metal cobalt-chromium stent versus a sirolimus-eluting stent for coronary revascularization. Catheter Cardiovasc Interv. 2007 May 1;69(6):790-8.
- Ostojic M, Sagic D, Beleslin B, Jung R, Perisic Z, Jagic N, Nedeljkovic M, Mangovski L, Milosavljevic B, Stojkovic S, Orlic D, Antonic Z, Miloradovic V, Topic D, Paunovic D. First clinical comparison of Nobori -Biolimus A9 eluting stents with Cypher- Sirolimus eluting stents: Nobori Core nine months angiographic and one year clinical outcomes. EuroIntervention. 2008 Mar;3(5):574-9.
- Park SW, Lee CW, Hong MK, Kim JJ, Cho GY, Nah DY, Park SJ. Randomized comparison of coronary stenting with optimal balloon angioplasty for treatment of lesions in small coronary arteries. Eur Heart J. 2000 Nov;21(21):1785-9.
- Rahel BM, Suttorp MJ, Laarman GJ, Kiemeneij F, Bal ET, Rensing BJ, Ernst SM, ten Berg JM, Kelder JC, Plokker HW. Primary stenting of occluded native coronary arteries: final results of the Primary Stenting of Occluded Native Coronary Arteries (PRISON) study. Am Heart J. 2004 May;147(5):e22.
- Rodriguez-Granillo GA, Valgimigli M, Garcia-Garcia HM, Ong AT, Aoki J, van Mieghem CA, Tsuchida K, Sianos G, McFadden E, van der Giessen WJ, van Domburg R, de Feyter P, Serruys PW. One-year clinical outcome after coronary stenting of very small vessels using 2.25 mm sirolimus- and paclitaxel-eluting stents: a comparison between the RESEARCH and T-SEARCH registries. J Invasive Cardiol. 2005 Aug;17(8):409-12.
- Rosenblum MA, Robbins MJ, Farkouh ME, Winston JA, Kim MC. Diminished benefits of drug-eluting stents versus bare metal stents in patients with severe renal insufficiency. Nephron Clin Pract. 2009;113(3):c198-202. doi: 10.1159/000232602. Epub 2009 Aug 12.
- Safian R.D. and Freed M., Complications. In: The Manual of Interventional Cardiology Jones & Bartlett Publishers, 2001. 381-467
- Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med. 1994 Aug 25;331(8):489-95.
- Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM, Weintraub WS, O'Rourke RA, Dada M, Spertus JA, Chaitman BR, Friedman J, Slomka P, Heller GV, Germano G, Gosselin G, Berger P, Kostuk WJ, Schwartz RG, Knudtson M, Veledar E, Bates ER, McCallister B, Teo KK, Boden WE; COURAGE Investigators. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008 Mar 11;117(10):1283-91. doi: 10.1161/CIRCULATIONAHA.107.743963. Epub 2008 Feb 11.
- Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med. 1987 Mar 19;316(12):701-6.
- Silber S, Albertsson P, Avilés FF, Camici PG, Colombo A, Hamm C, Jørgensen E, Marco J, Nordrehaug JE, Ruzyllo W, Urban P, Stone GW, Wijns W; Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J. 2005 Apr;26(8):804-47. Epub 2005 Mar 15.
- Stettler C, Allemann S, Egger M, Windecker S, Meier B, Diem P. Efficacy of drug eluting stents in patients with and without diabetes mellitus: indirect comparison of controlled trials. Heart. 2006 May;92(5):650-7. Epub 2005 Oct 26. Review.
- Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schömig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabaté M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Jüni P. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007 Sep 15;370(9591):937-48. Review.
- Stone GW. SPIRIT IV A Prospective, Randomized Trial Comparing an Everolimus Eluting Stent and a Paclitaxel Eluting Stent in Patients With Coronary Artery Disease One Year Clinical Results. 2009.
- Sukhija R, Mehta JL, Sachdeva R. Present status of coronary bifurcation stenting. Clin Cardiol. 2008 Feb;31(2):63-6. Review.
- Suttorp MJ, Laarman GJ, Rahel BM, Kelder JC, Bosschaert MA, Kiemeneij F, Ten Berg JM, Bal ET, Rensing BJ, Eefting FD, Mast EG. Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): a randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions. Circulation. 2006 Aug 29;114(9):921-8. Epub 2006 Aug 14.
- Tanimoto S, Daemen J, Serruys PW. Update on stents: recent studies on the TAXUS stent system in small vessels. Vasc Health Risk Manag. 2007;3(4):481-90. Review.
- Tillmanns H, Waas W, Voss R, Grempels E, Hölschermann H, Haberbosch W, Waldecker B. Gender differences in the outcome of cardiac interventions. Herz. 2005 Aug;30(5):375-89. Review. English, German.
- TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. N Engl J Med. 1985 Apr 4;312(14):932-6.
- Turco MA, Ormiston JA, Popma JJ, Mandinov L, O'Shaughnessy CD, Mann T, McGarry TF, Wu CJ, Chan C, Webster MW, Hall JJ, Mishkel GJ, Cannon LA, Baim DS, Koglin J. Polymer-based, paclitaxel-eluting TAXUS Liberté stent in de novo lesions: the pivotal TAXUS ATLAS trial. J Am Coll Cardiol. 2007 Apr 24;49(16):1676-83. Epub 2007 Apr 6.
- Urban P, Gershlick AH, Guagliumi G, Guyon P, Lotan C, Schofer J, Seth A, Sousa JE, Wijns W, Berge C, Deme M, Stoll HP; e-Cypher Investigators. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation. 2006 Mar 21;113(11):1434-41. Epub 2006 Mar 13.
- Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, Lenk K, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, di Mario C, Davies S, van Geuns RJ, Eerdmans P, van Es GA, Meier B, Jüni P. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet. 2008 Sep 27;372(9644):1163-73. doi: 10.1016/S0140-6736(08)61244-1. Epub 2008 Aug 31.
Responsible Party:
Terumo Europe N.V.
ClinicalTrials.gov Identifier:
NCT01261273
Other Study ID Numbers:
- T113E2
First Posted:
Dec 16, 2010
Last Update Posted:
Oct 9, 2019
Last Verified:
Oct 1, 2019
Keywords provided by Terumo Europe N.V.
Additional relevant MeSH terms: